Monte Rosa Therapeutics, Inc. (GLUE) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GLUE | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | oncology | oncology |
| Price and returns | ||
| Last close | $10.48 | $123.96 |
| Return · 1 week | −1.69% | 0.00% |
| Return · 1 month | −10.50% | 0.00% |
| Return · 3 months | −52.45% | 0.00% |
| Return · year to date | −31.55% | +22.93% |
| Return · 1 year | −14.94% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −59.33% | −0.02% |
| 52-week high | $25.77 | $123.99 |
| 52-week low | $8.94 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $894.08M | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $11.73M | $149.69M |
| Employees | 173 | 234 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 30.59× | — |
| Price to book | 1.80× | 8.33× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | — |
| Enterprise value to revenue | 9.90× | — |
| Earnings per share · trailing | -1.75 | -6.06 |
| Profitability | ||
| Operating margin | −547.84% | 0.00% |
| Profit margin | −560.85% | — |
| Return on equity | −42.66% | −41.19% |
| Return on assets | −21.63% | −22.51% |
| Growth | ||
| Revenue growth | −61.30% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 7.80 | — |
| Current ratio | 10.58 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 40.98 | — |
| ADX · 14 | 29.11 | — |
| 50-day average | $12.43 | — |
| 200-day average | $17.65 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 5.74% | — |
The full GLUE analysis
Everything this table leaves out for Monte Rosa Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GLUE argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GLUE analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis